

Kounis syndrome: An additional etiologic factor of myocardial infarction with non-obstructive coronary arteries

Nicholas G. Kounis¹, Ioanna Koniari², George D. Soufras³, Grigorios Tsigkas¹, Emmanouil Chourdakis⁴, Stefanos Despotopoulos¹, Periklis Davlouros¹, George Hahalís¹

¹Department of Cardiology, University of Patras Medical School, Rion, Patras, Achaia, Greece

²Department of Electrophysiology, Queen Elizabeth Hospital, Birmingham, England

³Department of Cardiology, “Saint Andrews” State General Hospital, Patras, Achaia, Greece

⁴Krankenhaus der Barmherzigen Brüder, Trier, Germany

In an interesting report published in the “Cardiology Journal” concerning 95 patients treated for myocardial infarction with non-obstructive coronary arteries (MINOCA), López Pais et al. [1] found that when non-takotsubo MINOCA patients were evaluated the difference regarding psychiatric illnesses was 29.7% vs. 12.9%, $p = 0.001$ compared to myocardial infarction (MI) with obstructive coronary arteries. Furthermore, in 11 (11.6%) of these patients, pathophysiological mechanisms of MINOCA remained unknown.

In another recent report, involving 998 patients with angiographically proven MI in the real world, 82 (8.2%) had a MINOCA and 40% were women. No evident etiology was detected in over 70% of MINOCA [2].

Therefore, it seems possible that new, yet unknown, pathophysiological mechanisms are involved in the pathogenesis of this conundrum.

So far, several other causes and pathogenetic mechanisms have been reported to be associated with this syndrome including coronary artery spasm, coronary artery dissection, coronary embolism, arrhythmias, mild plaque disruption, hypercoagulable status, type 2 MI, amyloid light-chain AL amyloidosis and clinically unrecognized myocarditis or takotsubo cardiomyopathy [2].

The prevalence of MINOCA among the MI patients ranged between 5% and 25% according to the registries [3]. In a recent report involving 199,163 MI admissions, 9092 consecutive unique

patients had MINOCA, 2147 of them experienced a new major adverse cardiovascular event (MACE) and 1254 (14%) of the patients died during mean follow-up of 4.5 years [4]. In this report, even after adjustment, low levels of total cholesterol were significantly associated with the composite endpoint of MACE as well as with long-term mortality. The authors had wondered about these results because hypercholesterolemia is considered as a causal factor for coronary artery disease and that the lowering of total cholesterol and low-density lipoprotein reduces cardiovascular risk in both primary and secondary prevention settings.

Indeed, it is being considered why, the Kounis hypersensitivity-associated type I variant coronary spasm which represents a manifestation of endothelial dysfunction or microvascular angina has not been included in this MINOCA report [1] as well as in others [5]. This variant includes patients with normal or nearly normal coronary arteries without predisposing factors for coronary artery disease and represents the most common type (72.6%) of Kounis syndrome. In this variant, the acute release of inflammatory mediators may induce either coronary artery spasm without increased cardiac enzymes and troponins or coronary artery spasm progressing to acute MI with raised cardiac enzymes and troponins. The ensuing acute MI could lead to MACE including cardiogenic shock (2.3%), cardiac arrest (6.3%), death 5 (2.9%) due to ventricular fibrillation,

Address for correspondence: Nicholas G. Kounis, MD, Queen Olga's Square, 7 Aratou Street, Patras 26221, Greece, e-mail: ngkounis@otenet.gr

Received: 23.04.2018

Accepted: 15.07.2018

anterior ST-segment elevation MI and inferior ST-segment elevation MI [6].

The hypersensitivity-related Kounis syndrome inclusion in the MINOCA heterogenic group could well explain this cholesterol paradox observed in the aforementioned study [4]. Indeed, children and adolescents with clinical and laboratory manifestations of atopy have shown lower cholesterol concentrations throughout infancy, childhood and adolescence as compared with non-atopic subjects [7].

Kounis syndrome is rarely diagnosed but is not a rare disease. Indeed, the annual incidence of Kounis syndrome at the emergency department among all admissions and patients with allergy was 19.4 per 100,000 (27 of 138,911) and 3.4% (27 of 793), respectively [8]. In a recent report from Japan [9] the annual incidence of Kounis syndrome at emergency departments of Numazu City Hospital, Shizuoka, from 2012 to 2017 in patients with anaphylaxis, was 2% (2 of 100) and of Shizuoka Hospital, Juntendo University, from 2013 to 2017, was 2.2% (3 of 138), respectively. It is concluded herein that Kounis syndrome should always be excluded when physicians treat patients with allergy.

Specific biomarkers should be measured in cases of a suspicion of Kounis syndrome in MINOCA patients. These should include measurements of serum tryptase, histamine, eosinophils, total immunoglobulins (IgEs), cardiac enzymes and cardiac troponins supplemented with electrocardiography, echocardiography, angiography and modern tools such as thallium-201 single-photon emission computed tomography and dynamic cardiac magnetic resonance imaging [10]. In cases of drug-induced MINOCA the following diagnostic tests including specific IgEs, radioallergosorbent testing, enzyme linked immunosorbent assay, fluoroenzyme immunoassay, drug provocation test, basophil activation test and skin prick tests should be always performed. When a diagnosis of Kounis syndrome is established, treating type I variant with corticosteroids, H1 and H2 antihistamines and calcium channel blockers and nitrates is indicated.

All of the above show that MINOCA disease is neither benign nor a rare clinical entity. Searching, therefore, for its etiology and treatment that will provide a way for improving prognosis is of paramount importance but it is not an easy task. It is suggested herein that every MINOCA patient should undergo thorough clinical and laboratory

diagnostic investigations in order to identify its causality and pathophysiological mechanisms. Future studies are necessary in order to dissolve the MINOCA conundrum.

Conflict of interest: None declared

References

1. Lopez Pais JL, Izquierdo Coronel B, Galán Gil D, et al. Psychoemotional disorders as incoming risk factors for myocardial infarction with non-obstructive coronary arteries. *Cardiol J*. 2018; 25(1): 24–31, doi: [10.5603/CJ.a2017.0139](https://doi.org/10.5603/CJ.a2017.0139), indexed in Pubmed: [29240964](https://pubmed.ncbi.nlm.nih.gov/29240964/).
2. Raparelli V, Elharram M, Shimony A, et al. Myocardial infarction with no obstructive coronary artery disease: angiographic and clinical insights in patients with premature presentation. *Can J Cardiol*. 2018; 34(4): 468–476, doi: [10.1016/j.cjca.2018.01.004](https://doi.org/10.1016/j.cjca.2018.01.004), indexed in Pubmed: [29571427](https://pubmed.ncbi.nlm.nih.gov/29571427/).
3. Montone RA, Niccoli G, Fracassi F, et al. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. *Eur Heart J*. 2018; 39(2): 91–98, doi: [10.1093/eurheartj/ehx667](https://doi.org/10.1093/eurheartj/ehx667), indexed in Pubmed: [29228159](https://pubmed.ncbi.nlm.nih.gov/29228159/).
4. Nordenskjöld AM, Baron T, Eggers KM, et al. Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease. *Int J Cardiol*. 2018; 261: 18–23, doi: [10.1016/j.ijcard.2018.03.056](https://doi.org/10.1016/j.ijcard.2018.03.056), indexed in Pubmed: [29563017](https://pubmed.ncbi.nlm.nih.gov/29563017/).
5. Agewall S, Beltrame JF, Reynolds HR, et al. WG on Cardiovascular Pharmacotherapy. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. *Eur Heart J*. 2017; 38(3): 143–153, doi: [10.1093/eurheartj/ehw149](https://doi.org/10.1093/eurheartj/ehw149), indexed in Pubmed: [28158518](https://pubmed.ncbi.nlm.nih.gov/28158518/).
6. Abdelghany M, Shah S, Subedi R, et al. Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome. *Int J Cardiol*. 2017; 232: 1–4, doi: [10.1016/j.ijcard.2017.01.124](https://doi.org/10.1016/j.ijcard.2017.01.124), indexed in Pubmed: [28153536](https://pubmed.ncbi.nlm.nih.gov/28153536/).
7. Pesonen M, Ranki A, Siimes MA, et al. Serum cholesterol level in infancy is inversely associated with subsequent allergy in children and adolescents. A 20-year follow-up study. *Clin Exp Allergy*. 2008; 38(1): 178–184, doi: [10.1111/j.1365-2222.2007.02875.x](https://doi.org/10.1111/j.1365-2222.2007.02875.x), indexed in Pubmed: [18028461](https://pubmed.ncbi.nlm.nih.gov/18028461/).
8. Akoz A, Tanboga HI, Emet M, et al. prospective study of Kounis syndrome: clinical experience and cardiac magnetic resonance imaging findings for 21 patients. *Acta Med Mediterraea*. 2013; 9: 811–816.
9. Yanagawa Y, Kondo A, Ishikawa K, et al. Kounis syndrome should be excluded when physicians treat patients with anaphylaxis. *Ann Allergy Asthma Immunol*. 2017; 119(4): 392, doi: [10.1016/j.anai.2017.08.003](https://doi.org/10.1016/j.anai.2017.08.003), indexed in Pubmed: [28958381](https://pubmed.ncbi.nlm.nih.gov/28958381/).
10. Kounis NG. Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management. *Clin Chem Lab Med*. 2016; 54(10): 1545–1559, doi: [10.1515/cclm-2016-0010](https://doi.org/10.1515/cclm-2016-0010), indexed in Pubmed: [26966931](https://pubmed.ncbi.nlm.nih.gov/26966931/).